Introduction
Cell4Cure AB, a Swedish biotech company founded in 2023, is pioneering immune tolerance therapies aimed at addressing significant clinical challenges such as anti-drug antibodies (ADAs), autoimmune diseases, and transplant rejection. The company’s proprietary platform leverages ex vivo-generated dendritic cells (DCs) engineered to induce antigen-specific immune tolerance.
These tolerogenic DCs offer a targeted approach to mitigating unwanted immune responses while preserving essential immune functions.
Cell4Cure’s primary focus is on Anti-Drug Antibodies (ADAs), a critical issue in conditions like severe hemophilia A, where 30% of patients develop neutralizing antibodies against factor VIII (FVIII) treatments. With our lead product, ItolDC-028, we are ready to initiate a Phase 1/2a clinical trial in Europe to evaluate its safety and efficacy in hemophilia A patients with ADAs.
This innovative therapy aims to restore responsiveness to FVIII, providing an alternative to conventional immune tolerance induction therapies.
Vision
& mission
Offer curative or correcting personalized cell therapies mediating antigen-specific tolerance via our proprietary technology platform
Provide solutions for severe clinical challenges in complex medical conditions
-
Anti-Drug Antibodies (ADAs)
-
Autoimmune Diseases
-
Transplant Rejections
Develop innovative alternatives to general immunosuppressive treatments to minimize their associated side effects, such as cancer and severe infections.
By focusing on achieving antigen-specific tolerance, our company strives to revolutionize the field and drive advancements in the treatment of these complex medical conditions, ultimately improving the quality of life for diverse patient groups.
